急性胸痛风险分层加速诊断路径的比较
该前瞻性三中心队列研究纳入4399例急诊胸痛患者,比较HEART路径与EDACS对30天主要不良心血管事件的识别能力。EDACS将更多患者归为低危(58.1% vs 38.4%),但低危组MACE发生率更高(1.0% vs 0.4%),HEART路径阴性预测值更高(99.6% vs 99.0%)。
要点
- EDACS低危比例更高,但漏诊MACE率也更高。
- HEART路径阴性预测值99.6%,高于EDACS的99.0%。
- 选择路径需结合医生对漏诊风险的容忍度。
核心结论
- EDACS识别低危患者比例高于HEART路径,但30天漏诊MACE率更高。
- HEART路径阴性预测值高于EDACS,需根据风险容忍度选择路径。
研究设计与样本
- 前瞻性三中心队列研究,纳入有急性冠脉综合征症状的成人急诊胸痛患者。
- 共纳入5799例,其中4399例完成HEART路径和EDACS评估。
- 通过电子健康记录、保险索赔和死亡索引确定30天MACE(死亡、心肌梗死和冠脉血运重建)。
主要发现
- 30天MACE发生率为449/4399(10.2%)。
- HEART路径将38.4%(95%CI 37.0%–39.9%)归为低危,EDACS为58.1%(95%CI 56.6%–59.6%),p<0.001。
- HEART路径低危组MACE发生率0.4%(95%CI 0.2%–0.9%),EDACS低危组1.0%(95%CI 0.7%–1.5%),p<0.001。
- HEART路径阴性预测值99.6%(95%CI 99.1%–99.8%),EDACS为99.0%(95%CI 98.5%–99.3%)。
临床怎么用
- 临床选择HEART路径或EDACS时需权衡低危患者比例与漏诊MACE风险。
- HEART路径阴性预测值更高,适合对漏诊风险容忍度低的场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The History Electrocardiogram Age Risk factor Troponin (HEART) Pathway and Emergency Department Assessment of Chest pain Score (EDACS) are validated accelerated diagnostic pathways designed to risk stratify patients presenting to the emergency department with chest pain. Data from large multisite prospective studies comparing these accelerated diagnostic pathways are limited. METHODS: The HEART Pathway Implementation is a prospective three-site cohort study, which accrued adults with symptoms concerning for acute coronary syndrome. Physicians completed electronic health record HEART Pathway and EDACS risk assessments on participants. Major adverse cardiac events (death, myocardial infarction and coronary revascularisation) at 30 days were determined using electronic health record, insurance claims and death index data. Test characteristics for detection of major adverse cardiac events were calculated for both accelerated diagnostic pathways and McNemar's tests were used for comparisons. RESULTS: 5799 patients presenting to the emergency department were accrued, of which HEART Pathway and EDACS assessments were completed on 4399. Major adverse cardiac events at 30 days occurred in 449/4399 (10.2%). The HEART Pathway identified 38.4% (95% CI 37.0% to 39.9%) of patients as low-risk compared with 58.1% (95% CI 56.6% to 59.6%) identified as low-risk by EDACS (p<0.001). Major adverse cardiac events occurred in 0.4% (95% CI 0.2% to 0.9%) of patients classified as low-risk by the HEART Pathway compared with 1.0% (95% CI 0.7% to 1.5%) of patients identified as low-risk by EDACS (p<0.001). Thus, the HEART Pathway had a negative predictive value of 99.6% (95% CI 99.1% to 99.8%) for major adverse cardiac events compared with a negative predictive value of 99.0% (95% CI 98.5% to 99.3%) for EDACS. CONCLUSIONS: EDACS identifies a larger proportion of patients as low-risk than the HEART Pathway, but has a higher missed major adverse cardiac events rate at 30 days. Physicians will need to consider their risk tolerance when deciding whether to adopt the HEART Pathway or EDACS accelerated diagnostic pathway. TRIAL REGISTRATION NUMBER: NCT02056964.
引用
- Stopyra J, Snavely AC, Hiestand B, et al. Comparison of accelerated diagnostic pathways for acute chest pain risk stratification. Heart. 2020. PMID: 32269131. doi:10.1136/heartjnl-2019-316426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。